Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Next Press Release to Watch Out For

<< Previous

Bullboard Posts

Next >>

Post by mstrmndon Oct 16, 2021 2:07pm

465 Views

Post# 34013625

Next Press Release to Watch Out For

It was confirmed at the AGM that preliminary data on COVID-19 has been obtained by ATE.TO.

I suspect, either ATB-346 or ATB-352 will be targeting either of the following indications as an oral therapeutic against COVID-19 progression:
1) Mild-to-Moderate COVID-19 (same market as Molnupiravir by Merck)
2) Long COVID

We now have proof that viral breakthrough will render COVID19 vaccines (present generation) ineffective, therefore the need for an oral therapeutic to reduce the severity of COVID19 has never been greater.

GLTA

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading